Prurisol – Chronic Plaque Psoriasis (Phase 2b Tr
Post# of 72440
(Total Views: 178)
Posted On: 02/16/2017 9:28:12 AM
Prurisol – Chronic Plaque Psoriasis (Phase 2b Trial)
- Subject recruitment is now ongoing across the United States. The study increases the total daily oral dosing of Prurisol from a previous high of 200 mg, which was shown to be well-tolerated in a successfully completed Phase 2a trial, to include oral Prurisol 300 mg per day, oral Prurisol 400 mg per day, and placebo (3:1:3 randomization). Enrolling approximately 189 patients with moderate to severe chronic plaque psoriasis, treatment duration is 12 weeks (84 days). Primary efficacy is being evaluated using the Psoriasis Area and Severity Index (PASI). The Company believes now is an opportune time to develop an oral treatment for psoriasis given that currently available treatment options are limited, with many not easily administered and often associated with undesirable side effects.
- Subject recruitment is now ongoing across the United States. The study increases the total daily oral dosing of Prurisol from a previous high of 200 mg, which was shown to be well-tolerated in a successfully completed Phase 2a trial, to include oral Prurisol 300 mg per day, oral Prurisol 400 mg per day, and placebo (3:1:3 randomization). Enrolling approximately 189 patients with moderate to severe chronic plaque psoriasis, treatment duration is 12 weeks (84 days). Primary efficacy is being evaluated using the Psoriasis Area and Severity Index (PASI). The Company believes now is an opportune time to develop an oral treatment for psoriasis given that currently available treatment options are limited, with many not easily administered and often associated with undesirable side effects.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼